Curve DAO
CRV
Below: live crypto price for Curve DAO (CRV), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Curve DAO (CRV) trades at 0.36 USD.
- Prev close
- $0.35
- Volume (24h)
- $1.35M
- Market cap
- $563.79M
- Currency
- USD
Score
36/ 100 · Weak
- Market cap rank—
- Momentum36
- Supply—
- Community—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 0.3601 +0.58%
- +20 bars
- 0.3629 +1.38%
- +60 bars
- 0.3641 +1.69%
- +120 bars
- 0.3641 +1.70%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0581 USD.
Interpretation
Composite signals look weak. Price sits in the middle of the recent range, trend is sloping upward.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Momentum36/100
Momentum looks weak — driven by 30-day change (3.71%).
30-day change:3.71% - Community—
Community looks mixed — driven by Social channels (0).
Social channels:0
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 400 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 89.1%
- Max drawdown
- -77.4%
- Below period high
- -56.8%
- Best day
- +21.17%
- Worst day
- -26.46%
- Up days
- 46%
- Current streak
- 1 up
- Typical day swing
- 7.4%
- Volume vs average
- -2%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 0.4159 high → 0.2655 low · 60 bars
- ResistanceFib +161.8% extensionnot reached0.6592 USD+84.15% from current
- ResistanceFib +100% extensionnot reached0.5663 USD+58.18% from current
- ResistanceFib +61.8% extensionnot reached0.5088 USD+42.14% from current
- ResistanceFib +27.2% extensionnot reached0.4568 USD+27.60% from current
- ResistanceFib 23.6% retracementtested 13×0.3804 USD+6.26% from current
- ResistanceFib 38.2% retracementNearesttested 28×0.3584 USD+0.12% from current
- Current0.358 USD
- SupportFib 50% midpointtested 28×0.3407 USD-4.83% from current
- SupportFib 61.8% retracementtested 15×0.323 USD-9.79% from current
- SupportFib 78.6% retracementtested 4×0.2977 USD-16.85% from current
- SupportFib −27.2% extensionnot reached0.2246 USD-37.27% from current
- SupportFib −61.8% extensionnot reached0.1726 USD-51.80% from current
- SupportFib −100% extensionnot reached0.1151 USD-67.85% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Buy CRV on
Recent news
- CareView Communications Announces New VA Business Agreements, Expands Relationship in VABusiness Wire5d ago
- CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026GlobeNewswire6d ago
- CareView Communications Announces New Contract with Care New EnglandBusiness Wire10d ago
- Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis SuppurativaGlobeNewswire18d ago
- CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure LimitGlobeNewswire20d ago
- Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?Simply Wall St.23d ago
- CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities ConferenceGlobeNewswire26d ago
- Raindrop Announces Series A and $50M in Total Funding Led by CRV to Protect the World from AI Agent FailuresBusiness Wire9/17/2026
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.